BIO PORT KOREA, INC.: debt-to-equity, ROE and more
KOSDAQ, Legal name BIO PORT KOREA, INC.
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 41.6%
- Equity ratio
- 70.6%
- ROE
- -3.5%
- Op. margin
- 1.2%
- Rev. growth
- -3.4%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
No dividend data yet for this company.
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 separate | 264.7% | 27.4% | 14.9% | 5.0% | n/a |
| FY2022 separate | 235.1% | 29.8% | 23.4% | 6.3% | 31.4% |
| FY2023 separate | 241.6% | 29.3% | 23.5% | 7.2% | 9.2% |
| FY2024 consolidated | 67.4% | 59.7% | 14.3% | 7.1% | 6.8% |
| FY2025 consolidated | 41.6% | 70.6% | -3.5% | 1.2% | -3.4% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩47.9B | ₩62.9B | ₩68.7B | ₩73.3B | ₩70.9B |
| Operating profit | ₩2.4B | ₩4.0B | ₩4.9B | ₩5.2B | ₩830.0M |
| Pre-tax income | ₩1.8B | ₩3.3B | ₩3.6B | ₩5.4B | -₩1.8B |
| Net income | ₩1.4B | ₩2.8B | ₩3.4B | ₩4.1B | -₩1.4B |
| Total assets | ₩33.5B | ₩39.9B | ₩49.0B | ₩48.0B | ₩57.3B |
| Total liabilities | ₩24.3B | ₩28.0B | ₩34.7B | ₩19.3B | ₩16.8B |
| Total equity | ₩9.2B | ₩11.9B | ₩14.4B | ₩28.7B | ₩40.5B |
| Paid-in capital | ₩500.0M | ₩500.0M | ₩500.0M | ₩727.8M | ₩935.9M |
| Debt/equity (source value) | 264.7% | 235.1% | 241.6% | 67.4% | 41.6% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 2004-11-11
- Listed
- 25/05/16
- Employees
- 112
- Auditor
- 삼정회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1801110500991
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 바이오포트Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.